This is a clinical data update with no near-term revenue catalyst. Monitor for potential biopharma partnership announcements or reimbursement developments following the ASCO presentations. The 97% detection rate and ultrasensitive range data are positive for the test's clinical positioning but do not change the near-term financial outlook.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 27 $3.93entry
- T+1 · 6mo ago +7.38%α +6.83% · $4.22
- T+5 · 6mo ago +9.67%α +8.46% · $4.31
- T+20 · 5mo ago +38.17%α +40.07% · $5.43
- T+60 · 3mo ago −18.07%α −19.95% · $3.22
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Myriad Genetics announced it will present data at ASCO 2026 showing its Precise MRD test achieved 97% baseline detection across multiple cancer types in the MONSTAR-SCREEN-3 study, with 16% of samples detected at ultrasensitive levels. The data supports the clinical utility of the test for recurrence monitoring, but this is a scientific conference presentation with no immediate revenue or regulatory catalyst.
Key Facts
- Precise MRD test achieved 97% baseline ctDNA detection in MONSTAR-SCREEN-3 pan-cancer analysis
- 16% of samples detected in the ultrasensitive range
- ctDNA-positive patients at 1-month post-surgery had significantly worse disease-free survival
- Data presented across six posters at ASCO 2026 covering gastric, ovarian, head/neck, sarcoma, and pan-cancer indications
- No financial terms, revenue guidance, or regulatory milestones disclosed in the press release
Financial Impact
No financial figures disclosed; the press release is a scientific data update with no immediate revenue or cost impact
Risk Factors
- No revenue or regulatory milestones announced; commercialization timeline for Precise MRD remains uncertain
- Competitive MRD tests from Guardant Health, Natera, and others may limit market share
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3302066 |
Track record
16 reports on MYGN
3 of 4 bullish or bearish reports moved the stock their way by T+1. Best: +13.54% at T+5 after the Oct 20, 2026 report. 3 of 4 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Bearish 4/10 Entry price pending
- Nov 9, 20267d ago 8-K Neutral 2/10 Entry $5.67 to $5.72 Now $5.57 −1.76% ▲ +0.88% −0.44% vs SPY
- Nov 5, 202611d ago 8-K Neutral 4/10 Entry $6.29 to $5.92 Now $5.57 −11.45% ▼ −5.88% −6.19% vs SPY
- Nov 4, 202612d ago 8-K Mixed 6/10 Entry $6.29 to $5.92 Now $5.57 −11.45% ▼ −5.88% −6.19% vs SPY
- Nov 4, 202612d ago Institutional Cluster Neutral 2/10 Entry $6.02 to $6.29 Now $5.57 −7.48% ▲ +4.49% +8.89% vs SPY
- Oct 27, 202620d ago SC 13G/A Neutral 2/10 Entry $6.63 to $6.67 Now $5.57 −15.99% ▲ +0.60% +0.99% vs SPY
- Oct 20, 202627d ago 8-K Bullish 7/10 Entry $5.54 to $5.57 Now $5.57 +0.54% ▲ +0.54% +0.02% vs SPY
- Oct 15, 20264w ago Press Release Neutral 1/10 Entry $3.98 Now $5.57 +39.95% No price data
- Oct 9, 20265w ago 8-K Neutral 3/10 Entry $4.20 to $4.08 Now $5.57 +32.62% ▼ −2.86% −2.85% vs SPY
- Sep 16, 20268w ago 8-K Neutral 3/10 Entry $3.86 to $4.14 Now $5.57 +44.30% ▲ +7.25% +6.12% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers